New migraine pill promises fast pain relief in Real-World study
NCT ID NCT05903027
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study is testing how well and how safely the drug rimegepant works for treating migraine attacks as they happen. Researchers will follow 100 people with migraine (with or without aura, or chronic migraine) who take a 75 mg rimegepant tablet when they have an attack. The main goal is to see if they are pain-free 2 hours after taking the drug, and to track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITINGPavia, 27100, Italy
Contact Email: •••••@•••••
-
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITINGFlorence, 50134, Italy
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rimegepant 75 mg orally disintegrating tablet
What this could lead to
If successful, this could confirm rimegepant as a reliable option for quickly stopping migraine pain in both episodic and chronic migraine patients.
What could go wrong
This is an observational study with only 100 participants, so results may not apply to everyone. Rimegepant may cause side effects or not work for all types of migraine.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.